ME 1111

Drug Profile

ME 1111

Alternative Names: ME-1111

Latest Information Update: 18 Apr 2016

Price : $50

At a glance

  • Originator Meiji Seika Pharma
  • Class Antifungals
  • Mechanism of Action Succinate cytochrome c oxidoreductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Onychomycosis

Most Recent Events

  • 18 Apr 2016 ME 1111 is still in phase II trials for Onychomycosis in USA (Topical)
  • 27 Aug 2014 Meiji Seika Pharma completes enrolment in its phase II trial for Onychomycosis in USA (NCT02022215)
  • 01 Dec 2013 Phase-II clinical trials in Onychomycosis in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top